Clinical trials: Treatment-resistant Depression
Depressive Disorder
Acute Efficacy and 6 Months Follow up After Electroconvulsive Therapy
The overall aim of the current project is to assess the acute and long term outcome of ECT (both patient and clinician rated) in a non-selected patient cohort from ordinary clinical activity, and to seek out factors predicting…
- Trial name
- NCT05388461
- Testing
- electroconvulsive therapy
- Where
- 2 sites in Norway
- Volunteers
- 600 people
- Sponsor
- Haukeland University Hospital
Post-Traumatic Stress Disorders, Major Depressive Disorder
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
Co-occurring post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) is the most common response to trauma; it is associated with poor clinical outcomes and substantial human disability.
- Trial name
- NCT04032301
- Testing
- Ketamine, Normal Saline
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Refractory Depression, Anxiety Disorders
Focused Ultrasound and Exosomes to Treat Depression, Anxiety, and Dementias
This study is designed to evaluate the safety and efficacy of exosome deployment with concurrent transcranial ultrasound in patients with refractory, treatment resistant depression, anxiety, and neurodegenerative dementia.
- Conditions
- Refractory Depression, Anxiety Disorders, Neurodegenerative Diseases
- Trial name
- NCT04202770
- Testing
- Exosomes
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Neurological Associates of West Los Angeles
Treatment Resistant Depression
The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
The primary objective of this study is to evaluate the efficacy of 25 mg of psilocybin under supportive conditions to adult participants with BP-II, current episode depressed, in improving depressive symptoms.
- Trial name
- NCT04433845
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sheppard Pratt Health System
Major Depressive Disorder (MDD)
Accelerated TMS for Treatment-Resistant ECT
This study investigates whether an additional treatment using transcranial magnetic stimulation (TMS) can help severely depressed patients who did not respond well to electroconvulsive therapy (ECT).
- Trial name
- A-TREC (NCT07115628)
- Testing
- Transcranial Magnetic Stimulation
- Where
- Belgium
- Volunteers
- 200 people
- Sponsor
- Universitair Ziekenhuis Brussel
Treatment Resistant Depression
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
The Safety and Efficacy of Psilocybin as an Adjunctive Therapy in Participants with Treatment-Resistant Depression
- Trial name
- NCT04739865
- Testing
- Psilocybin
- Where
- 2 sites in United States, Ireland
- Volunteers
- 19 people
- Sponsor
- COMPASS Pathways
Major Depressive Disorder
Treating Refractory Major Depressive Disorder With Repetitive Transcranial Magnetic Stimulation
Studies exploring the efficacy of repetitive transcranial magnetic stimulation (rTMS) as a treatment for refractory major depressive disorder (MDD) have shown significant promise.
- Trial name
- NCT00305045
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- Canada
- Volunteers
- 73 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder, Deep Brain Stimulation
The Efficacy and Prediction of Deep Brain Stimulation for Treatment-resistant Depression
Several open-label trials have shown the therapeutic promise of deep brain stimulation (DBS) targeted to striatal and surrounding capsular areas in treatment-resistant depression (TRD).
- Trial name
- NCT04530942
- Testing
- Deep brain stimulation(Active)
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Ruijin Hospital
Depressive Disorder, Treatment-Resistant
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
The purpose of this study is to evaluate how well each individual dose of esketamine (56 milligrams [mg] and 84 mg) works when compared with placebo in improving depressive symptoms in participants with treatment resistant…
- Trial name
- NCT07716098
- Testing
- Esketamine 56 mg, Esketamine 84 mg
- Where
- 22 sites in United States, Japan and 1 more
- Volunteers
- 348 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder, Unipolar Depression
RTMS Feasibility Study on Adolescent Depression Stimulation
This is an open-label study, in which all participants receives an active treatment with repetitive transcranial magnetic stimulation (rTMS) according to clinical protocol.
- Conditions
- Major Depressive Disorder, Unipolar Depression, Bipolar Depression
- Trial name
- NCT06126198
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Uppsala University
Bipolar Disorder
Treatment Resistant Depression in Bipolar Disorder - A Randomized Controlled Trial of Electroconvulsive Therapy
This project is a randomized controlled trial of electroconvulsive therapy (ECT) compared to treatment as usual (TAU) in the treatment of treatment resistant depression (TRD) in bipolar disorder.
- Trial name
- NCT00664976
- Testing
- Electroconvulsive therapy, Treatment as usual
- Where
- 2 sites in Norway
- Volunteers
- 73 people
- Sponsor
- Norwegian University of Science and Technology
Treatment Resistant Depression
A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
The purpose of this study is to assess the efficacy and safety of olanzapine and fluoxetine compared to placebo and fluoxetine as treatment for treatment-resistant depression (TRD) in Chinese participants.
- Trial name
- NCT01687478
- Testing
- Olanzapine, Fluoxetine
- Where
- 11 sites in China
- Volunteers
- 176 people
- Sponsor
- Eli Lilly and Company
Treatment-Resistant Depression
pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Depression
We aim to evaluate the safety and efficacy of pBFS-guided high-dose rTMS therapy with short inter-session interval for patients with treatment-resistant depression
- Trial name
- NCT05842291
- Testing
- Active rTMS with short inter-session interval, Active rTMS with long inter-session interval
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changping Laboratory
Depression
RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode
The study is a phase II, double-blind, randomized, placebo controlled, parallel, multicentric study in 110 patients with drug resistant depression.
- Trial name
- NCT03870776
- Testing
- MAP4343
- Where
- 10 sites in France
- Volunteers
- 126 people
- Sponsor
- Mapreg
Treatment-Resistant Depression
Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder
This is an ancillary study to a clinical trial that is being conducted at Massachusetts General Hospital. Investigators at MGH are conducting a clinical trial to test the efficacy of ziprasidone together with escitalopram for…
- Trial name
- NCT01598324
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mclean Hospital
Depression - Major Depressive Disorder
Effect of Neurofeedback and TMS
The goal of this clinical trial is to is to learn whether adding EEG neurofeedback (NFB) to repetitive transcranial magnetic stimulation (rTMS) is safe and feasible for adults with major depressive disorder (MDD).
- Trial name
- NCT07892287
- Testing
- Repetitive Transcranial Magnetic Stimulation, Alpha-down EEG Neurofeedback
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Treatment-Resistant
Treatment for Major Depressive Disorder With Intermittent Theta-burst Stimulation
The main purpose of this study is to investigate the two different intermittent Theta Burst (iTBS) repetitive transcranial magnetic stimulation (rTMS), its effectiveness in alleviating depressive symptoms.
- Trial name
- iTBS (NCT05390593)
- Testing
- iTBS-1800, iTBS-1200
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- Chang Gung Memorial Hospital
Treatment Resistant Depression
Pharmacogenomics for Antidepressant Guidance and Education
More than one out of three individuals treated for major depressive disorder (MDD) do not experience a full reduction of symptoms even when treated with adequate antidepressant medication.
- Trial name
- NCT01555021
- Testing
- Genotyping assays
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Massachusetts General Hospital
Major Depression
Deep Brain Stimulation of the Superolateral Branch of the Medial Forebrain Bundle (slMFB) for the Treatment of Refractory Major Depression
The investigators will investigate in a sham controlled staggered onset design antidepressant effects and safety of deep brain stimulation (DBS) to the superolateral branch of the main medial forebrain bundle (slMFB).
- Trial name
- FORESEEII (NCT01778790)
- Testing
- Deep Brain Stimulation with Activa PC Multi-program Neurostimulator
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- University Hospital, Bonn
Treatment Resistant Depression
Accelerated Intermittent Theta Burst Stimulation for Depressed Patients During the Covid-19 Pandemic
Repetitive Transcranial Magnetic Stimulation (rTMS) using intermittent theta burst stimulation (iTBS) has been found to be a non inferior protocol to standard rTMS for the treatment of major depressive disorder.
- Trial name
- NCT04935489
- Testing
- Intermittent Theta Burst Stimulation (form of repetitive transcranial magnetic stimulation) given in an accelerated form
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ontario Shores Centre for Mental Health Sciences